Lantheus Holdings, Inc. (NASDAQ:LNTH) CFO Robert J. Jr. Marshall Sells 10,000 Shares

Lantheus Holdings, Inc. (NASDAQ:LNTH) CFO Robert J. Jr. Marshall sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the sale, the chief financial officer now owns 113,860 shares of the company’s stock, valued at $11,445,207.20. The trade was a 8.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Lantheus Stock Performance

Lantheus stock opened at $97.71 on Friday. The company has a 50 day moving average price of $92.67 and a 200 day moving average price of $96.64. Lantheus Holdings, Inc. has a 52 week low of $57.92 and a 52 week high of $126.89. The firm has a market capitalization of $6.69 billion, a price-to-earnings ratio of 16.26 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. Equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lantheus

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State of New Jersey Common Pension Fund D lifted its position in Lantheus by 0.4% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider’s stock worth $2,364,000 after buying an additional 115 shares in the last quarter. Bleakley Financial Group LLC lifted its position in Lantheus by 6.1% in the 4th quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider’s stock worth $200,000 after buying an additional 129 shares in the last quarter. Avantax Advisory Services Inc. lifted its position in Lantheus by 5.9% in the 4th quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider’s stock worth $213,000 after buying an additional 132 shares in the last quarter. Foundry Partners LLC lifted its position in Lantheus by 4.5% in the 4th quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider’s stock worth $278,000 after buying an additional 133 shares in the last quarter. Finally, UMB Bank n.a. lifted its position in Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after buying an additional 134 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. The Goldman Sachs Group assumed coverage on shares of Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price for the company. B. Riley reduced their target price on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a report on Friday. JMP Securities restated a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. Finally, Truist Financial raised their target price on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $129.43.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.